CUE BIOPHARMA INC. -

Cue Biopharma’s Therapeutic Immuno-STAT Biologics to be Featured in Oxford University Presentation at the 67th Biophysical Society Annual Meeting

16 фев 2023 10:30:00 Источник Nasdaq GlobeNewswire

Cue Biopharma Announces the Appointment of Dr. Rafi Ahmed to its Scientific Advisory Board

16 фев 2023 08:00:01 Источник Nasdaq GlobeNewswire

Cue Biopharma to Present at Two February 2023 Scientific Conferences

01 фев 2023 08:00:01 Источник Nasdaq GlobeNewswire

Cue Biopharma Announces Chief Medical Officer Transition

23 янв 2023 08:00:00 Источник Nasdaq GlobeNewswire

Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences

22 ноя 2022 08:00:04 Источник Nasdaq GlobeNewswire

Cue Biopharma Reports Third Quarter 2022 Financial Results

14 ноя 2022 16:01:00 Источник Nasdaq GlobeNewswire

Cue Biopharma Announces $30 Million Private Investment in Public Equity (PIPE) Financing

14 ноя 2022 08:20:14 Источник Nasdaq GlobeNewswire

Cue Biopharma Presents New Positive Data from Ongoing Phase 1 Trial of CUE-101 in Combination with KEYTRUDA(R) for Recurrent/Metastatic HPV+ Head and Neck Cancer at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

10 ноя 2022 09:00:03 Источник Nasdaq GlobeNewswire

Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in November

09 ноя 2022 08:00:03 Источник Nasdaq GlobeNewswire

Cue Biopharma to Host Business Update Call and Webcast

07 ноя 2022 08:00:02 Источник Nasdaq GlobeNewswire

Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

05 окт 2022 08:00:01 Источник Nasdaq GlobeNewswire

Cue Biopharma Granted FDA Fast Track Designation for CUE-101 for the Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

04 окт 2022 08:00:01 Источник Nasdaq GlobeNewswire

Cue Biopharma to Present at Two September 2022 Scientific Conferences

07 сен 2022 08:00:01 Источник Nasdaq GlobeNewswire

Cue Biopharma Doses First Patient in Phase 1 Study of CUE-102 for Wilms’ Tumor 1 (WT1) - expressing cancers

22 авг 2022 08:00:01 Источник Nasdaq GlobeNewswire

Cue Biopharma Reports Second Quarter 2022 Financial Results

04 авг 2022 16:30:00 Источник Nasdaq GlobeNewswire

Cue Biopharma to Present at the Guggenheim I&I Spotlight Series

11 июл 2022 08:00:00 Источник Nasdaq GlobeNewswire

Cue Biopharma to Present at the JMP Securities Life Sciences Conference

13 июн 2022 08:00:01 Источник Nasdaq GlobeNewswire

Cue Biopharma to Present at the Jefferies Healthcare Conference

01 июн 2022 08:00:00 Источник Nasdaq GlobeNewswire

Cue Biopharma to Present at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

26 май 2022 17:00:00 Источник Nasdaq GlobeNewswire

Cue Biopharma Receives FDA Acceptance of Investigational New Drug (IND) Application for CUE-102 in Wilms’ Tumor 1 (WT1) - expressing cancers

11 май 2022 08:01:12 Источник Nasdaq GlobeNewswire